TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Travere Therapeutics, Inc.
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$50.49+0.89 (+1.79%)
Close on Oct 19, 2026
- Market cap
- $4.72B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
106M of 94M shares
Institutional holders
319
89 new, 28 sold out
Net institutional buying
16M
In Q2 2026
Insider trades, 12 months
0 buys · 121 sales
Net sold $104.24M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC | 7,142,482 | 7.70% | 13G (passive) amendment | Jun 30, 2026 |
| Steven Boyd | 6,724,000 | 7.52% | 13G (passive) amendment | Sep 30, 2025 |
| BlackRock, Inc. | 6,689,435 | 7.50% | 13G (passive) amendment | Mar 31, 2025 |
| Bank Of America Corp /De/ | 5,439,155 | 5.80% | 13G (passive) | Jun 30, 2026 |
| Mark Bussard | 4,973,649 | 5.72% | 13G (passive) amendment | Dec 31, 2024 |
| Macquarie Investment Management Business Trust | 4,797,314 | 5.41% | 13G (passive) amendment | Mar 31, 2025 |
| Vanguard Capital Management | 4,699,424 | 5.09% | 13G (passive) | Mar 31, 2026 |
| Janus Henderson Group PLC | 10,599,660 | 11.90% | 13G (passive) amendment | Sep 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TVTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 11,324,191 | 12.01% | $643.30M | New | 0.26% |
| BlackRock, Inc. | 8,020,663 | 8.51% | $455.65M | +228,630 | 0.01% |
| FMR LLC | 7,096,614 | 7.53% | $403.16M | −3,871,353 | 0.02% |
| Bank Of America Corp /De/ | 4,568,341 | 4.85% | $259.53M | +3,223,230 | 0.02% |
| State Street Corp | 4,256,224 | 4.52% | $241.80M | −703,764 | 0.01% |
| Vanguard Capital Management LLC | 4,108,694 | 4.36% | $233.41M | +62,882 | 0.00% |
| Perceptive Advisors LLC | 3,752,574 | 3.98% | $213.18M | −389,977 | 3.20% |
| Nomura Asset Management International Inc. | 2,812,514 | 2.98% | $159.78M | −457,999 | 0.24% |
| Adage Capital Partners Gp, L.L.C. | 2,569,356 | 2.73% | $145.97M | +1,592,356 | 0.20% |
| Geode Capital Management, LLC | 2,371,887 | 2.52% | $134.77M | +2,328 | 0.01% |
| Rock Springs Capital Management LP | 2,179,069 | 2.31% | $123.79M | +701,115 | 6.04% |
| Kynam Capital Management, LP | 2,000,000 | 2.12% | $113.62M | +430,982 | 6.28% |
| Stephens Investment Management Group LLC | 1,875,304 | 1.99% | $106.54M | +76,838 | 1.14% |
| Renaissance Technologies LLC | 1,833,079 | 1.94% | $104.14M | −133,700 | 0.14% |
| Emerald Advisers, LLC | 1,600,886 | 1.70% | $90.95M | +43,690 | 2.14% |
| Armistice Capital, LLC | 1,572,539 | 1.67% | $89.34M | −3,324,878 | 1.09% |
| Two Sigma Investments, LP | 1,565,656 | 1.66% | $88.94M | +57,397 | 0.06% |
| Vanguard Portfolio Management LLC | 1,541,617 | 1.64% | $87.58M | −167,522 | 0.00% |
| Goldman Sachs Group Inc | 1,535,321 | 1.63% | $87.22M | −184,400 | 0.01% |
| Wellington Management Group Llp | 1,533,080 | 1.63% | $87.09M | +510,808 | 0.02% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 319 | 106M | 100.0% | 89 / 121 | 86 / 28 | 32M | 16M |
| Q1 2026 | 261 | 101M | 100.0% | 49 / 90 | 93 / 59 | 20M | 14M |
| Q4 2025 | 278 | 102M | 100.0% | 77 / 90 | 94 / 35 | 21M | 20M |
| Q3 2025 | 238 | 101M | 100.0% | 55 / 74 | 79 / 27 | 18M | 17M |
| Q2 2025 | 212 | 101M | 100.0% | 41 / 75 | 70 / 46 | 17M | 14M |
| Q1 2025 | 218 | 98M | 100.0% | 45 / 89 | 55 / 23 | 19M | 14M |
| Q4 2024 | 197 | 95M | 100.0% | 48 / 74 | 53 / 28 | 24M | 13M |
| Q3 2024 | 178 | 84M | 88.8% | 29 / 62 | 57 / 24 | 22M | 19M |
| Q2 2024 | 174 | 89M | 94.4% | 30 / 72 | 50 / 28 | 12M | 18M |
| Q1 2024 | 175 | 95M | 100.0% | 31 / 65 | 47 / 21 | 13M | 8M |
| Q4 2023 | 165 | 90M | 95.7% | 32 / 58 | 52 / 36 | 21M | 14M |
| Q3 2023 | 169 | 83M | 87.6% | 35 / 66 | 49 / 34 | 22M | 21M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of TVTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,947,890 | 3.13% | $167.47M | 0.01% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 2,580,388 | 2.74% | $121.74M | 0.05% | May 31, 2026 |
| iShares Russell 2000 ETF | 2,294,953 | 2.43% | $130.38M | 0.16% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,130,135 | 2.26% | $121.01M | 1.13% | Jun 30, 2026 |
| Nomura Small Cap Core Fund | 2,086,017 | 2.21% | $98.42M | 1.78% | May 29, 2026 |
| Vanguard Explorer Fund | 1,431,331 | 1.52% | $80.00M | 0.36% | Jul 31, 2026 |
| Janus Henderson Global Life Sciences Fund | 1,413,117 | 1.50% | $80.28M | 1.38% | Jun 30, 2026 |
| Janus Henderson Triton Fund | 1,118,321 | 1.19% | $63.53M | 1.07% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,066,372 | 1.13% | $60.58M | 0.06% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 977,006 | 1.04% | $54.60M | 0.16% | Jul 31, 2026 |
| Fidelity Blue Chip Growth Fund | 913,923 | 0.97% | $51.08M | 0.05% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 825,375 | 0.88% | $46.89M | 0.30% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 798,843 | 0.85% | $37.69M | 0.72% | May 31, 2026 |
| Fidelity Small Cap Growth Fund | 743,290 | 0.79% | $41.54M | 0.47% | Jul 31, 2026 |
| iShares Biotechnology ETF | 640,421 | 0.68% | $36.38M | 0.40% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Eric M. Dube | CHIEF EXECUTIVE OFFICER, Director | 439,688 | 0.47% | Sep 17, 2026 |
| Peter Heerma | EVP, CHIEF COMMERCIAL OFFICER | 117,066 | 0.12% | Sep 17, 2026 |
| Elizabeth E. Reed | Chief Legal Officer and GC | 142,889 | 0.15% | Sep 17, 2026 |
| Jula Inrig | EVP, Head of R&D & CMO | 102,491 | 0.11% | Sep 17, 2026 |
| Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | 47,728 | 0.05% | Sep 17, 2026 |
| William E. Rote | Chief Research Officer | 98,197 | 0.10% | Sep 17, 2026 |
| Christopher R. Cline | CHIEF FINANCIAL OFFICER | 87,908 | 0.09% | Sep 17, 2026 |
| Jeffrey A. Meckler | Director | 109,800 | 0.12% | Sep 11, 2026 |
| Gary A. Lyons | Director | 62,400 | 0.07% | Aug 19, 2026 |
| Roy D. Baynes | Director | 46,000 | 0.05% | Jun 16, 2026 |
| Timothy Coughlin | Director | 56,250 | 0.06% | Jun 16, 2026 |
| Brinkley Ruth Williams | Director | 29,750 | 0.03% | May 21, 2026 |
| Suzanne Louise Bruhn | Director | 32,750 | 0.03% | May 21, 2026 |
| Ron Squarer | Director | 39,375 | 0.04% | May 21, 2026 |
| Sandra Poole | Director | 34,000 | 0.04% | May 21, 2026 |
| John A. Orwin | Director | 39,375 | 0.04% | May 21, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Sep 17, 2026 | Sale(10b5-1 plan) | −101,691 | $64.59 | $6.57M | 439,688 |
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Sep 17, 2026 | Option exercise | +108,493 | $23.34 | $2.53M | 541,379 |
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Sep 17, 2026 | Sale(10b5-1 plan) | −6,802 | $64.95 | $441.79K | 432,886 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | Sep 17, 2026 | Sale(10b5-1 plan) | −8,282 | $65.07 | $538.91K | 117,066 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | Sep 17, 2026 | Option exercise | +8,282 | $22.40 | $185.52K | 125,348 |
| William E. Rote Chief Research Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −47,746 | $63.61 | $3.04M | 98,197 |
| William E. Rote Chief Research Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −65,104 | $63.12 | $4.11M | 145,943 |
| William E. Rote Chief Research Officer | Sep 16, 2026 | Option exercise | +57,500 | $26.88 | $1.55M | 211,047 |
| William E. Rote Chief Research Officer | Sep 16, 2026 | Option exercise | +55,000 | $15.46 | $850.30K | 153,547 |
| William E. Rote Chief Research Officer | Sep 16, 2026 | Option exercise | +350 | $17.96 | $6.29K | 98,547 |
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Sep 16, 2026 | Option exercise | +195,841 | $23.34 | $4.57M | 628,727 |
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Sep 16, 2026 | Sale(10b5-1 plan) | −96,125 | $63.64 | $6.12M | 432,886 |
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Sep 16, 2026 | Sale(10b5-1 plan) | −99,716 | $63.26 | $6.31M | 529,011 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | Sep 16, 2026 | Option exercise | +100,000 | $11.25 | $1.13M | 217,066 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | Sep 16, 2026 | Sale(10b5-1 plan) | −79,113 | $63.65 | $5.04M | 117,066 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | Sep 16, 2026 | Sale(10b5-1 plan) | −93,604 | $63.25 | $5.92M | 196,179 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | Sep 16, 2026 | Option exercise | +17,717 | $26.88 | $476.23K | 289,783 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | Sep 16, 2026 | Option exercise | +55,000 | $15.46 | $850.30K | 272,066 |
| Christopher R. Cline CHIEF FINANCIAL OFFICER | Sep 15, 2026 | Sale(10b5-1 plan) | −1,900 | $63.69 | $121.01K | 87,908 |
| Christopher R. Cline CHIEF FINANCIAL OFFICER | Sep 15, 2026 | Sale(10b5-1 plan) | −20,735 | $62.61 | $1.30M | 89,808 |
| Christopher R. Cline CHIEF FINANCIAL OFFICER | Sep 15, 2026 | Sale(10b5-1 plan) | −400 | $65.31 | $26.12K | 87,508 |
| Christopher R. Cline CHIEF FINANCIAL OFFICER | Sep 15, 2026 | Option exercise | +20,000 | $17.44 | $348.80K | 138,016 |
| Christopher R. Cline CHIEF FINANCIAL OFFICER | Sep 15, 2026 | Sale(10b5-1 plan) | −27,473 | $62.00 | $1.70M | 110,543 |
| Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | Sep 15, 2026 | Option exercise | +1,625 | $20.46 | $33.25K | 47,728 |
| Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | Sep 15, 2026 | Sale(10b5-1 plan) | −800 | $62.85 | $50.28K | 42,653 |
| Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | Sep 15, 2026 | Sale(10b5-1 plan) | −4,275 | $62.14 | $265.65K | 43,453 |
| Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | Sep 15, 2026 | Sale(10b5-1 plan) | −300 | $63.66 | $19.10K | 42,353 |
| Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | Sep 15, 2026 | Option exercise | +1,250 | $22.40 | $28.00K | 46,103 |
| Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | Sep 15, 2026 | Option exercise | +2,500 | $27.50 | $68.75K | 44,853 |
| William E. Rote Chief Research Officer | Sep 15, 2026 | Option exercise | +39,650 | $17.96 | $712.11K | 194,395 |
| William E. Rote Chief Research Officer | Sep 15, 2026 | Option exercise | +39,000 | $25.25 | $984.75K | 154,745 |
| William E. Rote Chief Research Officer | Sep 15, 2026 | Sale(10b5-1 plan) | −270 | $65.31 | $17.63K | 98,197 |
| William E. Rote Chief Research Officer | Sep 15, 2026 | Sale(10b5-1 plan) | −3,000 | $63.65 | $190.95K | 98,467 |
| William E. Rote Chief Research Officer | Sep 15, 2026 | Sale(10b5-1 plan) | −29,021 | $62.66 | $1.82M | 101,467 |
| William E. Rote Chief Research Officer | Sep 15, 2026 | Sale(10b5-1 plan) | −63,907 | $61.99 | $3.96M | 130,488 |
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −270 | $65.31 | $17.63K | 432,886 |
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −3,102 | $63.64 | $197.41K | 433,156 |
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −28,796 | $62.66 | $1.80M | 436,258 |
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −63,498 | $61.99 | $3.94M | 465,054 |
| Eric M. Dube CHIEF EXECUTIVE OFFICER, Director | Sep 15, 2026 | Option exercise | +95,666 | $23.34 | $2.23M | 528,552 |
| Jula Inrig EVP, Head of R&D & CMO | Sep 15, 2026 | Sale(10b5-1 plan) | −17,284 | $62.62 | $1.08M | 102,491 |
| Jula Inrig EVP, Head of R&D & CMO | Sep 15, 2026 | Sale(10b5-1 plan) | −1,600 | $63.69 | $101.90K | 100,891 |
| Jula Inrig EVP, Head of R&D & CMO | Sep 15, 2026 | Sale(10b5-1 plan) | −400 | $65.31 | $26.12K | 100,491 |
| Jula Inrig EVP, Head of R&D & CMO | Sep 15, 2026 | Sale(10b5-1 plan) | −25,390 | $62.02 | $1.57M | 119,775 |
| Jula Inrig EVP, Head of R&D & CMO | Sep 15, 2026 | Option exercise | +32,395 | $8.93 | $289.29K | 145,165 |
| Elizabeth E. Reed Chief Legal Officer and GC | Sep 15, 2026 | Option exercise | +37,500 | $15.46 | $579.75K | 142,889 |
| Elizabeth E. Reed Chief Legal Officer and GC | Sep 15, 2026 | Sale(10b5-1 plan) | −21,926 | $62.03 | $1.36M | 120,963 |
| Elizabeth E. Reed Chief Legal Officer and GC | Sep 15, 2026 | Sale(10b5-1 plan) | −13,874 | $62.63 | $868.93K | 107,089 |
| Elizabeth E. Reed Chief Legal Officer and GC | Sep 15, 2026 | Sale(10b5-1 plan) | −300 | $65.31 | $19.59K | 105,389 |
| Elizabeth E. Reed Chief Legal Officer and GC | Sep 15, 2026 | Sale(10b5-1 plan) | −1,400 | $63.69 | $89.17K | 105,689 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | Sep 15, 2026 | Option exercise | +39,283 | $26.88 | $1.06M | 181,349 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | Sep 15, 2026 | Option exercise | +1,381 | $22.40 | $30.93K | 182,730 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | Sep 15, 2026 | Option exercise | +36,526 | $8.93 | $326.18K | 219,256 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | Sep 15, 2026 | Sale(10b5-1 plan) | −71,938 | $62.05 | $4.46M | 147,318 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | Sep 15, 2026 | Sale(10b5-1 plan) | −27,421 | $62.59 | $1.72M | 119,897 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | Sep 15, 2026 | Sale(10b5-1 plan) | −1,400 | $63.65 | $89.11K | 118,497 |
| Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | Sep 15, 2026 | Sale(10b5-1 plan) | −1,431 | $65.31 | $93.46K | 117,066 |
| Jeffrey A. Meckler Director | Sep 10, 2026 | Sale(10b5-1 plan) | −1,700 | $65.39 | $111.16K | 109,800 |
| Jeffrey A. Meckler Director | Sep 10, 2026 | Option exercise | +10,000 | $17.44 | $174.40K | 101,500 |
| Jeffrey A. Meckler Director | Sep 10, 2026 | Option exercise | +10,000 | $26.52 | $265.20K | 111,500 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Dube Eric Director, Officer | Oct 15, 2026 | 243,735 | $12.98M | Oct 15, 2026 | Exercise of Stock Options |
| Dube Eric Director, Officer | Sep 17, 2026 | 108,493 | $6.89M | Sep 17, 2026 | Exercise of Stock Options |
| Heerma Peter Officer | Sep 17, 2026 | 8,282 | $525.74K | Sep 17, 2026 | Exercise of Stock Options |
| Dube Eric Director, Officer | Sep 16, 2026 | 195,841 | $12.24M | Sep 16, 2026 | Exercise of Stock Options |
| Heerma Peter Officer | Sep 16, 2026 | 172,717 | $10.80M | Sep 16, 2026 | Exercise of Stock Options |
| Rote William Officer | Sep 16, 2026 | 112,850 | $7.05M | Sep 16, 2026 | Exercise of Stock Options |
| Calvin Sandra Officer | Sep 15, 2026 | 5,375 | $353.62K | Sep 15, 2026 | Exercise of Stock Options |
| Cline Christopher Officer | Sep 15, 2026 | 50,508 | $3.32M | Sep 15, 2026 | Exercise of Stock Options |
| Reed Elizabeth Officer | Sep 15, 2026 | 39,576 | $2.60M | Sep 15, 2026 | Exercise of Stock Options |
| Dube Eric Director, Officer | Sep 15, 2026 | 95,666 | $6.29M | Sep 15, 2026 | Exercise of Stock Options |
| Heerma Peter Officer | Sep 15, 2026 | 102,190 | $6.72M | Sep 15, 2026 | Exercise of Stock Options |
| Rote William Officer | Sep 15, 2026 | 96,198 | $6.33M | Sep 15, 2026 | Exercise of Stock Options |
| Inrig Jula Officer | Sep 15, 2026 | 44,674 | $2.94M | Sep 15, 2026 | Exercise of Stock Options |
| Meckler Jeffrey Director | Sep 10, 2026 | 20,000 | $1.32M | Sep 10, 2026 | Exercise of Stock Options |
| Lyons Gary Director | Aug 18, 2026 | 5,000 | $317.65K | Aug 18, 2026 | Exercise of Stock Options |